MAIA Biotechnology expects $33M capital raise to fund Phase 3 trial of anticancer therapy (MAIA:NYSE)

MAIA Biotechnology expects $33M capital raise to fund Phase 3 trial of anticancer therapy (MAIA:NYSE)

MAIA Biotechnology (MAIA) on Wednesday said the net proceeds from its $33 million public offering of common stock in March 2026 are expected to fully fund the company’s ongoing pivotal Phase 3 clinical trial of its lead investigational To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.

Related Posts

About FHMnews

What is FHMnews?

FHMnews is the result of a rebellion that transcended frustration. Look around you. As PK puts it, the people in this circle think one thing, say another, and do another. We shook up all three, confined within one circle, and decided to write as they think and speak. News, views, and everything beyond.

FHMnews is the country's first "new age" English news website. It's modern in its language, attitude, and news standards. It features selected news stories from the day, but with 360-degree coverage. It offers a complete report and analysis of each story, along with additional features like quizzes, polls, memes, and videos.

FHMnews Ltd.

E-43, Phase 8
Sahibzada Ajit Singh Nagar,
Punjab, 160071

Get In Touch With Us

© Copyright FHMnews